title: Reversible impaired memory induced by pulsed methylprednisolone in patients with MS.
abstract: Thirty patients with multiple sclerosis were randomized to 500 or 2,000 mg of methylprednisolone (MP) over 5 days. They were prospectively studied neuropsychologically before and at days 6 and 60 after onset of the therapy, using a double-blind study design. Patients showed selective deterioration of declarative memory retrieval at day 6, which was fully reversible at day 60. Although the sample size was small, these effects were independent of the administered MP dose.
authors.affiliation: Neurologische Klinik der Universität Ulm I, D-89081 Ulm, Germany. ingo.uttner@medizin.uni-ulm.de
authors.forename: I
authors.initials: I
authors.lastname: Uttner
authors.forename: S
authors.initials: S
authors.lastname: Müller
authors.forename: C
authors.initials: C
authors.lastname: Zinser
authors.forename: M
authors.initials: M
authors.lastname: Maier
authors.forename: S
authors.initials: S
authors.lastname: Süssmuth
authors.forename: A
authors.initials: A
authors.lastname: Claus
authors.forename: B
authors.initials: B
authors.lastname: Ostermann
authors.forename: E
authors.initials: E
authors.lastname: Elitok
authors.forename: D
authors.initials: D
authors.lastname: Ecker
authors.forename: J
authors.initials: J
authors.lastname: Brettschneider
authors.forename: R
authors.initials: R
authors.lastname: Gold
authors.forename: H
authors.initials: H
authors.lastname: Tumani
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006624:Hippocampus / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced* / Q000503:physiopathology; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011446:Prospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone